表皮生长因子受体2和雌激素受体及孕激素受体在乳腺癌中的表达及相关性分析

Expression and correlation of HER2,ER,PR in 113 cases with the breast cancer in Guangdong province

目的探讨表皮生长因子受体2(HER2)和雌激素受体(ER)及孕激素受体(PR)在乳腺癌中的表达及相关性,并提出HER2检测的优化程序,从而有利于HER2检测的准确性和可重复性,更准确地筛选出适用Herceptin靶向基因治疗的患者。方法免疫组织化学SP三步法对113例广东地区乳腺癌患者HER2、ER、PR表达进行检测。结果在本组113例乳腺癌患者中HER2表达的阳性率为24.78%,ER表达的阳性率为61.95%,PR表达的阳性率为67.26%,HER2表达与乳腺癌TNM分期、患者年龄、淋巴结转移、肿瘤大小无关(P>0.05);HER2表达与ER、PR表达情况有关(P<0.01),且呈负相关。结论广东地区女性乳腺癌HER2和ER及PR之间的表达相互关联,并在乳腺癌的确定治疗对策中扮演着重要角色。HER2检测的准确性和重复性,有赖于如何优化HER2状况检测程序。

Objective To detect the expression of HER2,ER,PR and to analyse the correlation of HER2,ER and PR expression with clinicopathological factors in the 113 patients with the breast cancer. To index how to optimize the HER2 detecting procedure,it was very helpful in the veracity and repetition of HER2 detecting,also in screening out the patients who needed the target treatment of HER2 accurately. Methods We examined the expression of HER2,ER and PR by immmunohistochemical SP methods. Results ( 1) The positivity rate of HER2,ER,PR protein expression was 24. 78% ,61. 95% and 67. 26% ,respectively. The positivity rate of HER2 protein expression was correlated with the expression of ER and PR ( P < 0. 05) ,but not with TNM stage,age,lymph nodes metastasis and the maximal diameter of tumors ( P > 0. 05) . Conclusions The expression of HER2 was correlated with the expression of ER and PR. HER2 may serve as a key role for evaluating the treatment policy of the breast cancer. The veracity and repetition of HER2 detecting depends on how to optimize the HER2 detecting procedure.